MaaT Pharma Reports FDA Feedback After Pre-IND Meeting on MaaT034
MaaT Pharma said FDA feedback following a pre-IND meeting supports continued development of MaaT034 in solid tumors.
Story updates
04:30:56 PM UTC
SquawkNews
MaaT Pharma said the FDA found its proposed, risk-based development approach for MaaT034 appropriate pending full IND review and indicated no additional nonclinical safety studies are required. The company targets a first-in-human study in late 2027, subject to clearances and funding.Material Detai…